Clinical trial • Other

DEXMEDETOMIDINE for Procedural sedation | Procedural pain

Clinical trial of DEXMEDETOMIDINE for Procedural sedation | Procedural pain.

Overview

Trial Therapeutic Area
Other
Trial Disease
Procedural sedation | Procedural pain
Drug Modality
Small molecule
Paediatric Trial
Yes

Key dates

Initial CTIS Submission Date
08-10-2024
First CTIS Authorization Date
05-11-2024

Trial design

Randomised, sodium chloride (placebo) intranasal, delivered using mad nasal™ intranasal mucosal atomization device; product max total amount indicated as 1 ml (placebo).-controlled trial across 1 site in Finland.

Randomised
Yes
Comparator
Sodium chloride (placebo) intranasal, delivered using MAD Nasal™ Intranasal Mucosal Atomization Device; product max total amount indicated as 1 ml (placebo).
Target Sample Size
112
Trial Duration For Participant
1

Eligibility

Recruits 112 paediatric patients.

Vulnerable Population
Includes pediatric participants aged 1-12; vulnerable population selected. Informed consent is obtained from parent(s). Age-appropriate informed consent/assent forms are provided (documents listed: "Informed consent, parent"; "Informed consent, 6-9 years of age"; "Informed consent, 10-12 years of age"). Documents/translations available in Finnish.

Inclusion criteria

  • {"criterion_text":"- Age 1-12 years\n- Small procedure (e.g. i.v. cannulation or lumbar puncture)\n- Presents at the Oulu University Hospital emergency room"}

Exclusion criteria

  • {"criterion_text":"- Allergy to dexmedetomidine or any supplementary elements of the dexmedetomidine-solution\n- II or III degree AV-blockage without pacemaker\n- Uncontrollable hypotension\n- Stroke\n- Critically ill patients who are admitted to the Pediatric Intensive Care Unit\n- Patients with clear cardiac or respiratory dysfunction\n- Lowered level of consciousness\n- Patients with increased risk of apnoeic events due to neurologic or metabolic conditions or extreme obesity\n- Prior participation to the current study"}

Endpoints

Primary endpoints

  • {"endpoint_text":"- The success of the procedure at the first attempt","definition_or_measurement_approach":""}

Secondary endpoints

  • {"endpoint_text":"- The duration of the procedure","definition_or_measurement_approach":""}
  • {"endpoint_text":"- Parents assessment of the patients comfortability during the procedure","definition_or_measurement_approach":"Parents' assessment using a Likert scale (as indicated in translations)."}
  • {"endpoint_text":"- Patient's and physician's assessment of the experienced pain with Visual Analog Scale","definition_or_measurement_approach":"Pain assessed by patient and physician using Visual Analog Scale (VAS)."}
  • {"endpoint_text":"- Assessment of pain levels of the patient with FLACC-scores","definition_or_measurement_approach":"Pain assessed using FLACC score."}
  • {"endpoint_text":"- Assessment of sedation levels of the patient with Comfort-B-scores","definition_or_measurement_approach":"Sedation assessed using the COMFORT-B sedation scale."}
  • {"endpoint_text":"- Duration of crying","definition_or_measurement_approach":"Measured in minutes from the moment the patient receives the intranasal study drug until the procedure is successfully completed."}
  • {"endpoint_text":"- The parents and the emergency room nurses are asked whether they think the patient recieved the experimental drug or placebo","definition_or_measurement_approach":"Parental and nurse assessment of perceived treatment allocation (experimental drug vs placebo)."}
  • {"endpoint_text":"- Blood pressure measured by manometer","definition_or_measurement_approach":"Blood pressure measurement by manometer."}
  • {"endpoint_text":"- Respiratory rate assessed by capnometry","definition_or_measurement_approach":"Respiratory rate measured by capnometry."}
  • {"endpoint_text":"- Oxygen saturation is measured by pulse oxymetry","definition_or_measurement_approach":"Oxygen saturation measured by pulse oximetry."}
  • {"endpoint_text":"- Heart rate measured by ECG","definition_or_measurement_approach":"Heart rate measured by ECG."}

Recruitment

Planned Sample Size
112
Recruitment Window Months
141
Consent Approach
Parental informed consent required. Age-appropriate assent/information forms provided: separate documents for 'Informed consent, parent', 'Informed consent, 6-9 years of age', and 'Informed consent, 10-12 years of age'. Documents/translations available in Finnish.

Methods

  • Patients presenting to the Oulu University Hospital pediatric emergency room who require a minor painful procedure (e.g. IV cannulation or lumbar puncture) are approached and asked to join the study at the point of care in the emergency room (site: Finland, Oulu University Hospital).

Geography

Total Number Of Sites
1
Total Number Of Participants
112

Finland

Earliest CTIS Part Ii Submission Date
18-10-2024
Latest Decision Or Authorization Date
05-11-2024
Processing Time Days
18
Number Of Sites
1
Number Of Participants
112

Sites

Site Name
Oulu University Hospital
Department Name
Department of Pediatrics and Adolescence
Contact Person Name
Outi Peltoniemi
Number Of Participants
112

Sponsor

Primary sponsor

Full Name
Oulu University Hospital
Organisation Type
Hospital/Clinic/Other health care facility
Country Of Registered Address
Finland

Investigational products

Investigational Product Name
DEXMEDETOMIDINE
Active Substance
DEXMEDETOMIDINE
Modality
Small molecule
Routes Of Administration
INTRANASAL USE
Route
INTRANASAL USE
Starting Dose
1 μg/kg
Dose Levels
1 μg/kg
Frequency
Single administration
Maximum Dose
100 µg
Investigational Product Name
SODIUM CHLORIDE
Active Substance
SODIUM CHLORIDE
Modality
Small molecule
Routes Of Administration
INTRANASAL USE
Route
INTRANASAL USE
Starting Dose
up to 1 ml (placebo, max total amount indicated)
Dose Levels
up to 1 ml
Frequency
Single administration
Maximum Dose
1 ml

Related trials

Other published trials that may interest you.